Intervention not reported
Long cephalomedullary nail (2 studies; 400 participants)a · older adults (> 60 years of age) with extracapsular hip fractures
It is very uncertain whether the intervention changes long cephalomedullary nail (2 studies; 400 participants)a (very low certainty).
1 finding from 1 review
Intervention not reported
Short cephalomedullary nail (33 studies; 5380 participants)a · older adults (> 60 years of age) with extracapsular hip fractures
It is very uncertain whether the intervention changes short cephalomedullary nail (33 studies; 5380 participants)a (very low certainty).
1 finding from 1 review
Intervention not reported
Condylocephalic nail (6 studies; 847 participants)a · older adults (> 60 years of age) with extracapsular hip fractures
It is very uncertain whether the intervention changes condylocephalic nail (6 studies; 847 participants)a (very low certainty).
1 finding from 1 review
Intervention not reported
External fixation (1 study; 100 participants)a · older adults (> 60 years of age) with extracapsular hip fractures
The intervention showed no clear difference in external fixation (1 study; 100 participants)a (low certainty).
1 finding from 1 review
Intervention not reported
Hemiarthroplasty (No direct evidence, indirect evidence only) · older adults (> 60 years of age) with extracapsular hip fractures
It is very uncertain whether the intervention changes hemiarthroplasty (No direct evidence, indirect evidence only) (very low certainty).
1 finding from 1 review
RR 1.36 [0.73, 2.54]
Studies not reported
Very low
Intervention not reported
Non‐operative treatment (1 study; 106 participants)a · older adults (> 60 years of age) with extracapsular hip fractures
The intervention showed no clear difference in non‐operative treatment (1 study; 106 participants)a (low certainty).
1 finding from 1 review
Intervention not reported
Total hip arthroplasty (1 study; 156 participants)a · older adults (> 60 years of age) with extracapsular hip fractures
The intervention showed no clear difference in total hip arthroplasty (1 study; 156 participants)a (low certainty).
1 finding from 1 review
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every 4 weeks probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every 4 weeks showed no clear difference in adverse events at ≥ 12 months compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants with sustained remission (as defined by study investigators) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants with sustained remission (as defined by… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Mean time to first relapse after induction of remission (weeks) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants who did not need escape therapy (as defined by study investigators) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher proportion of participants who did not need escape therapy (as… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
QoL · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every 4 weeks probably leads to higher proportion of participants with relapse‐free survival at ≥ 12 months compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review